This is consistent with the recent results reported by Kumagai et al. [45], showing that a profound reactivation of effector PD‐1+CD8+ T cells is necessary for tumor regression, which paves the way for a promising predictive biomarker for PD‐1 blockade therapies. The gene discussed is CD8A; the disease is neoplasm.